Mohsen Marzban and Anahita Torkaman Boutorabi
Iranshahr University of Medical Sciences and Health Services, Iran
Tehran University of Medical Sciences, Iran
Posters & Accepted Abstracts: J Cell Sci Ther
Aim: Cell therapy for multiple sclerosis (MS) has become one of the newest therapies, even in its clinical phase. We
used thyroid hormone subcutaneously to enhance effects of the transplanted stem cells for remyelination in corpus
callosum.
Methods: First, human bone marrow mesenchymal stem cells (BM-MSCs) are cultured with �±-MEM containing 10%
fetal bovine serum (FBS). Demyelination model was induced in mice for 6 weeks by administration of the cuprizone,
and in the fourth and fifth week after the first dose of cuprizone, the stem cells were administered intraperitoneally
to the mice. From the fourth week to the end of the sixth week, the thyroid hormone was subcutaneously injected
into the mice. At the end of the sixth week, the mice were killed and subjected to tissue evaluations using the luxol
fast blue (LFB) staining technique for myelin pods also myelin basic protein (MBP) and platelet derived growth
factor (PDGF)-�± receptor immunohistochemistry. The expression of MBP, TR-�²1, TR-�²2 genes was investigated by
realTime-PCR.
Results: In histology studies, demyelination has been induced by cuprizone, and this is clearly evident in the luxol fast
blue staining and immunohistochemistry and molecular techniques. In the luxol fast blue and immunohistochemistry
technique for MBP and PDGF-�±R increased recovery in the combination group with the cell and the T3 hormone
was seen compared to other groups. In the molecular studies, the combination group did significantly increase the
expression of the MBP, TR-�²1 and TR-�²2 genes. However, TR-�²2 gene played a more significant role.
Conclusion: In groups where we used combined cell and thyroid injection, we observed an increase in myelination
compared to other groups that we used only from cells or hormone.
E-mail: mohsen136051@yahoo.com
